Development and Validation of a Risk Prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - ABCD-10

Megan H. Noe, Misha Rosenbach, Rebecca A. Hubbard, Arash Mostaghimi, Adela R. Cardones, Jennifer K. Chen, Jonathan Cotliar, Mark D.P. Davis, Arturo Dominguez, Lindy P. Fox, Lauren C. Hughey, Benjamin H. Kaffenberger, Daniel Kroshinsky, Bernice Y. Kwong, Daniel D. Miller, Amy Musiek, Alex Ortega Loayza, Victoria R. Sharon, Kanade Shinkai, Erika M. Summers & 6 others Karolyn A. Wanat, David A. Wetter, Scott Worswick, David J. Margolis, Joel M. Gelfand, Robert G. Micheletti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Importance: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score of Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate and underestimate SJS/TEN-related in-hospital mortality in various populations. Objective: To derive a risk prediction model for in-hospital mortality among patients with SJS/TEN and to compare prognostic accuracy with the SCORTEN model in a multi-institutional cohort of patients in the United States. Design, Setting, and Participants: Data from a multicenter cohort of patients 18 years and older treated for SJS/TEN between January 1, 2000, and June 1, 2015, were obtained from inpatient consult databases and electronic medical record systems at 18 medical centers in the United States as part of the Society for Dermatology Hospitalists. A risk model was derived based on data from 370 of these patients. Model discrimination (calculated as area under the receiver operating characteristic curve [AUC]) and calibration (calculated as predicted vs observed mortality, and examined using the Hosmer-Lemeshow goodness-of-fit statistic) were assessed, and the predictive accuracy was compared with that of SCORTEN. All analysis took place between December 2016 and April 2018. Main Outcomes and Measures: In-hospital mortality. Results: Among 370 patients (mean [SD] age 49.0 [19.1] years; 195 [52.7%] women), 54 (15.14%) did not survive to hospital discharge. Five covariates, measured at the time of admission, were independent predictors of in-hospital mortality: age in years (odds ratio [OR], 1.05; 95% CI, 1.02-1.07), body surface area (BSA) in percentage of epidermal detachment (OR, 1.02; 95% CI, 1.01-1.04), serum bicarbonate level below 20 mmol/L (OR, 2.90; 95% CI, 1.43-5.88), active cancer (OR, 4.40; 95% CI, 1.82-10.61), and dialysis prior to admission (OR, 15.94; 95% CI, 3.38-66.30). A severity-of-illness score was calculated by taking the sum of 1 point each for age 50 years or older, epidermal detachment greater than 10% of BSA, and serum bicarbonate level below 20 mmol/L; 2 points for the presence of active cancer; and 3 points for dialysis prior to admission. The score was named ABCD-10 (age, bicarbonate, cancer, dialysis, 10% BSA). The ABCD-10 model showed good discrimination (AUC, 0.816; 95% CI, 0.759-0.872) and calibration (Hosmer-Lemeshow goodness of fit test, P =.03). For SCORTEN, on admission, the AUC was 0.827 (95% CI, 0.774-0.879) and was not significantly different from that of the ABCD-10 model (P =.72). Conclusions and Relevance: In this cohort of patients with SJS/TEN, ABCD-10 accurately predicted in-hospital mortality, with discrimination that was not significantly different from SCORTEN. Additional research is needed to validate ABCD-10 in other populations. Future use of a new mortality prediction model may provide improved prognostic information for contemporary patients, including those enrolled in observational studies and therapeutic trials.

Original languageEnglish (US)
Pages (from-to)448-454
Number of pages7
JournalJAMA Dermatology
Volume155
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Stevens-Johnson Syndrome
Bicarbonates
Hospital Mortality
Dialysis
Neoplasms
Odds Ratio
Body Surface Area
Area Under Curve
Calibration
Mortality
Hospitalists
Electronic Health Records
Dermatology
Serum
ROC Curve
Population
Observational Studies
Inpatients
Outcome Assessment (Health Care)
Databases

ASJC Scopus subject areas

  • Dermatology

Cite this

Development and Validation of a Risk Prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - ABCD-10. / Noe, Megan H.; Rosenbach, Misha; Hubbard, Rebecca A.; Mostaghimi, Arash; Cardones, Adela R.; Chen, Jennifer K.; Cotliar, Jonathan; Davis, Mark D.P.; Dominguez, Arturo; Fox, Lindy P.; Hughey, Lauren C.; Kaffenberger, Benjamin H.; Kroshinsky, Daniel; Kwong, Bernice Y.; Miller, Daniel D.; Musiek, Amy; Ortega Loayza, Alex; Sharon, Victoria R.; Shinkai, Kanade; Summers, Erika M.; Wanat, Karolyn A.; Wetter, David A.; Worswick, Scott; Margolis, David J.; Gelfand, Joel M.; Micheletti, Robert G.

In: JAMA Dermatology, Vol. 155, No. 4, 01.04.2019, p. 448-454.

Research output: Contribution to journalArticle

Noe, MH, Rosenbach, M, Hubbard, RA, Mostaghimi, A, Cardones, AR, Chen, JK, Cotliar, J, Davis, MDP, Dominguez, A, Fox, LP, Hughey, LC, Kaffenberger, BH, Kroshinsky, D, Kwong, BY, Miller, DD, Musiek, A, Ortega Loayza, A, Sharon, VR, Shinkai, K, Summers, EM, Wanat, KA, Wetter, DA, Worswick, S, Margolis, DJ, Gelfand, JM & Micheletti, RG 2019, 'Development and Validation of a Risk Prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - ABCD-10', JAMA Dermatology, vol. 155, no. 4, pp. 448-454. https://doi.org/10.1001/jamadermatol.2018.5605
Noe, Megan H. ; Rosenbach, Misha ; Hubbard, Rebecca A. ; Mostaghimi, Arash ; Cardones, Adela R. ; Chen, Jennifer K. ; Cotliar, Jonathan ; Davis, Mark D.P. ; Dominguez, Arturo ; Fox, Lindy P. ; Hughey, Lauren C. ; Kaffenberger, Benjamin H. ; Kroshinsky, Daniel ; Kwong, Bernice Y. ; Miller, Daniel D. ; Musiek, Amy ; Ortega Loayza, Alex ; Sharon, Victoria R. ; Shinkai, Kanade ; Summers, Erika M. ; Wanat, Karolyn A. ; Wetter, David A. ; Worswick, Scott ; Margolis, David J. ; Gelfand, Joel M. ; Micheletti, Robert G. / Development and Validation of a Risk Prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - ABCD-10. In: JAMA Dermatology. 2019 ; Vol. 155, No. 4. pp. 448-454.
@article{3089bb4380994f74b3ca26fb87338b63,
title = "Development and Validation of a Risk Prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - ABCD-10",
abstract = "Importance: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score of Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate and underestimate SJS/TEN-related in-hospital mortality in various populations. Objective: To derive a risk prediction model for in-hospital mortality among patients with SJS/TEN and to compare prognostic accuracy with the SCORTEN model in a multi-institutional cohort of patients in the United States. Design, Setting, and Participants: Data from a multicenter cohort of patients 18 years and older treated for SJS/TEN between January 1, 2000, and June 1, 2015, were obtained from inpatient consult databases and electronic medical record systems at 18 medical centers in the United States as part of the Society for Dermatology Hospitalists. A risk model was derived based on data from 370 of these patients. Model discrimination (calculated as area under the receiver operating characteristic curve [AUC]) and calibration (calculated as predicted vs observed mortality, and examined using the Hosmer-Lemeshow goodness-of-fit statistic) were assessed, and the predictive accuracy was compared with that of SCORTEN. All analysis took place between December 2016 and April 2018. Main Outcomes and Measures: In-hospital mortality. Results: Among 370 patients (mean [SD] age 49.0 [19.1] years; 195 [52.7{\%}] women), 54 (15.14{\%}) did not survive to hospital discharge. Five covariates, measured at the time of admission, were independent predictors of in-hospital mortality: age in years (odds ratio [OR], 1.05; 95{\%} CI, 1.02-1.07), body surface area (BSA) in percentage of epidermal detachment (OR, 1.02; 95{\%} CI, 1.01-1.04), serum bicarbonate level below 20 mmol/L (OR, 2.90; 95{\%} CI, 1.43-5.88), active cancer (OR, 4.40; 95{\%} CI, 1.82-10.61), and dialysis prior to admission (OR, 15.94; 95{\%} CI, 3.38-66.30). A severity-of-illness score was calculated by taking the sum of 1 point each for age 50 years or older, epidermal detachment greater than 10{\%} of BSA, and serum bicarbonate level below 20 mmol/L; 2 points for the presence of active cancer; and 3 points for dialysis prior to admission. The score was named ABCD-10 (age, bicarbonate, cancer, dialysis, 10{\%} BSA). The ABCD-10 model showed good discrimination (AUC, 0.816; 95{\%} CI, 0.759-0.872) and calibration (Hosmer-Lemeshow goodness of fit test, P =.03). For SCORTEN, on admission, the AUC was 0.827 (95{\%} CI, 0.774-0.879) and was not significantly different from that of the ABCD-10 model (P =.72). Conclusions and Relevance: In this cohort of patients with SJS/TEN, ABCD-10 accurately predicted in-hospital mortality, with discrimination that was not significantly different from SCORTEN. Additional research is needed to validate ABCD-10 in other populations. Future use of a new mortality prediction model may provide improved prognostic information for contemporary patients, including those enrolled in observational studies and therapeutic trials.",
author = "Noe, {Megan H.} and Misha Rosenbach and Hubbard, {Rebecca A.} and Arash Mostaghimi and Cardones, {Adela R.} and Chen, {Jennifer K.} and Jonathan Cotliar and Davis, {Mark D.P.} and Arturo Dominguez and Fox, {Lindy P.} and Hughey, {Lauren C.} and Kaffenberger, {Benjamin H.} and Daniel Kroshinsky and Kwong, {Bernice Y.} and Miller, {Daniel D.} and Amy Musiek and {Ortega Loayza}, Alex and Sharon, {Victoria R.} and Kanade Shinkai and Summers, {Erika M.} and Wanat, {Karolyn A.} and Wetter, {David A.} and Scott Worswick and Margolis, {David J.} and Gelfand, {Joel M.} and Micheletti, {Robert G.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1001/jamadermatol.2018.5605",
language = "English (US)",
volume = "155",
pages = "448--454",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Development and Validation of a Risk Prediction Model for In-Hospital Mortality among Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - ABCD-10

AU - Noe, Megan H.

AU - Rosenbach, Misha

AU - Hubbard, Rebecca A.

AU - Mostaghimi, Arash

AU - Cardones, Adela R.

AU - Chen, Jennifer K.

AU - Cotliar, Jonathan

AU - Davis, Mark D.P.

AU - Dominguez, Arturo

AU - Fox, Lindy P.

AU - Hughey, Lauren C.

AU - Kaffenberger, Benjamin H.

AU - Kroshinsky, Daniel

AU - Kwong, Bernice Y.

AU - Miller, Daniel D.

AU - Musiek, Amy

AU - Ortega Loayza, Alex

AU - Sharon, Victoria R.

AU - Shinkai, Kanade

AU - Summers, Erika M.

AU - Wanat, Karolyn A.

AU - Wetter, David A.

AU - Worswick, Scott

AU - Margolis, David J.

AU - Gelfand, Joel M.

AU - Micheletti, Robert G.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Importance: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score of Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate and underestimate SJS/TEN-related in-hospital mortality in various populations. Objective: To derive a risk prediction model for in-hospital mortality among patients with SJS/TEN and to compare prognostic accuracy with the SCORTEN model in a multi-institutional cohort of patients in the United States. Design, Setting, and Participants: Data from a multicenter cohort of patients 18 years and older treated for SJS/TEN between January 1, 2000, and June 1, 2015, were obtained from inpatient consult databases and electronic medical record systems at 18 medical centers in the United States as part of the Society for Dermatology Hospitalists. A risk model was derived based on data from 370 of these patients. Model discrimination (calculated as area under the receiver operating characteristic curve [AUC]) and calibration (calculated as predicted vs observed mortality, and examined using the Hosmer-Lemeshow goodness-of-fit statistic) were assessed, and the predictive accuracy was compared with that of SCORTEN. All analysis took place between December 2016 and April 2018. Main Outcomes and Measures: In-hospital mortality. Results: Among 370 patients (mean [SD] age 49.0 [19.1] years; 195 [52.7%] women), 54 (15.14%) did not survive to hospital discharge. Five covariates, measured at the time of admission, were independent predictors of in-hospital mortality: age in years (odds ratio [OR], 1.05; 95% CI, 1.02-1.07), body surface area (BSA) in percentage of epidermal detachment (OR, 1.02; 95% CI, 1.01-1.04), serum bicarbonate level below 20 mmol/L (OR, 2.90; 95% CI, 1.43-5.88), active cancer (OR, 4.40; 95% CI, 1.82-10.61), and dialysis prior to admission (OR, 15.94; 95% CI, 3.38-66.30). A severity-of-illness score was calculated by taking the sum of 1 point each for age 50 years or older, epidermal detachment greater than 10% of BSA, and serum bicarbonate level below 20 mmol/L; 2 points for the presence of active cancer; and 3 points for dialysis prior to admission. The score was named ABCD-10 (age, bicarbonate, cancer, dialysis, 10% BSA). The ABCD-10 model showed good discrimination (AUC, 0.816; 95% CI, 0.759-0.872) and calibration (Hosmer-Lemeshow goodness of fit test, P =.03). For SCORTEN, on admission, the AUC was 0.827 (95% CI, 0.774-0.879) and was not significantly different from that of the ABCD-10 model (P =.72). Conclusions and Relevance: In this cohort of patients with SJS/TEN, ABCD-10 accurately predicted in-hospital mortality, with discrimination that was not significantly different from SCORTEN. Additional research is needed to validate ABCD-10 in other populations. Future use of a new mortality prediction model may provide improved prognostic information for contemporary patients, including those enrolled in observational studies and therapeutic trials.

AB - Importance: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score of Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate and underestimate SJS/TEN-related in-hospital mortality in various populations. Objective: To derive a risk prediction model for in-hospital mortality among patients with SJS/TEN and to compare prognostic accuracy with the SCORTEN model in a multi-institutional cohort of patients in the United States. Design, Setting, and Participants: Data from a multicenter cohort of patients 18 years and older treated for SJS/TEN between January 1, 2000, and June 1, 2015, were obtained from inpatient consult databases and electronic medical record systems at 18 medical centers in the United States as part of the Society for Dermatology Hospitalists. A risk model was derived based on data from 370 of these patients. Model discrimination (calculated as area under the receiver operating characteristic curve [AUC]) and calibration (calculated as predicted vs observed mortality, and examined using the Hosmer-Lemeshow goodness-of-fit statistic) were assessed, and the predictive accuracy was compared with that of SCORTEN. All analysis took place between December 2016 and April 2018. Main Outcomes and Measures: In-hospital mortality. Results: Among 370 patients (mean [SD] age 49.0 [19.1] years; 195 [52.7%] women), 54 (15.14%) did not survive to hospital discharge. Five covariates, measured at the time of admission, were independent predictors of in-hospital mortality: age in years (odds ratio [OR], 1.05; 95% CI, 1.02-1.07), body surface area (BSA) in percentage of epidermal detachment (OR, 1.02; 95% CI, 1.01-1.04), serum bicarbonate level below 20 mmol/L (OR, 2.90; 95% CI, 1.43-5.88), active cancer (OR, 4.40; 95% CI, 1.82-10.61), and dialysis prior to admission (OR, 15.94; 95% CI, 3.38-66.30). A severity-of-illness score was calculated by taking the sum of 1 point each for age 50 years or older, epidermal detachment greater than 10% of BSA, and serum bicarbonate level below 20 mmol/L; 2 points for the presence of active cancer; and 3 points for dialysis prior to admission. The score was named ABCD-10 (age, bicarbonate, cancer, dialysis, 10% BSA). The ABCD-10 model showed good discrimination (AUC, 0.816; 95% CI, 0.759-0.872) and calibration (Hosmer-Lemeshow goodness of fit test, P =.03). For SCORTEN, on admission, the AUC was 0.827 (95% CI, 0.774-0.879) and was not significantly different from that of the ABCD-10 model (P =.72). Conclusions and Relevance: In this cohort of patients with SJS/TEN, ABCD-10 accurately predicted in-hospital mortality, with discrimination that was not significantly different from SCORTEN. Additional research is needed to validate ABCD-10 in other populations. Future use of a new mortality prediction model may provide improved prognostic information for contemporary patients, including those enrolled in observational studies and therapeutic trials.

UR - http://www.scopus.com/inward/record.url?scp=85062699114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062699114&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2018.5605

DO - 10.1001/jamadermatol.2018.5605

M3 - Article

VL - 155

SP - 448

EP - 454

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 4

ER -